Researchmoz added Most up-to-date research on "Respiratory Tract Infections Drug Development Pipeline Review, 2018" to its huge collection of research reports.
This report provides an overview of the pipeline landscape for respiratory tract infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for tuberculosis, diphtheria and pertussis (whooping cough), and features dormant and discontinued products.
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1877889
Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in the body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest. There are 206 products in development for this indication.
Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics. There are 31 products in development for this indication.
Pertussis is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antibiotics. There are 40 products in development for this indication.
Molecular targets acted on by products in development for respiratory tract infections include bacterial proteins and toxins. Companies operating in this pipeline space include Beijing Minhai Biotechnology, Sanofi and GlaxoSmithKline.
Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
View Complete TOC with tables & Figures @ https://www.researchmoz.us/respiratory-tract-infections-drug-development-pipeline-review-2018-report.html/toc
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
List of Tables:
Table 1: Number of Products under Development for Tuberculosis 9
Table 2: Number of Products under Development by Companies Tuberculosis 11
Table 3: Number of Products under Development by Universities/Institutes Tuberculosis 14
Table 4: Products under Development by Companies Tuberculosis 16
Table 5: Products under Development by Universities/Institutes Tuberculosis 21
Table 6: Number of Products under Development for Diphtheria 25
Table 7: Number of Products under Development by Companies Diphtheria 27
Table 8: Number of Products under Development by Universities/Institutes Diphtheria 28
Table 9: Products under Development by Companies Diphtheria 29
Table 10: Products under Development by Universities/Institutes Diphtheria 31
Table 11: Number of Products under Development for Pertussis (Whooping Cough) 32
Table 12: Number of Products under Development by Companies Pertussis (Whooping Cough) 34
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1877889
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us ;
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow us on Blogger at : https://marketreportandanalysis.blogspot.com
This report provides an overview of the pipeline landscape for respiratory tract infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for tuberculosis, diphtheria and pertussis (whooping cough), and features dormant and discontinued products.
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1877889
Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in the body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest. There are 206 products in development for this indication.
Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics. There are 31 products in development for this indication.
Pertussis is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antibiotics. There are 40 products in development for this indication.
Molecular targets acted on by products in development for respiratory tract infections include bacterial proteins and toxins. Companies operating in this pipeline space include Beijing Minhai Biotechnology, Sanofi and GlaxoSmithKline.
Scope
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
View Complete TOC with tables & Figures @ https://www.researchmoz.us/respiratory-tract-infections-drug-development-pipeline-review-2018-report.html/toc
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
List of Tables:
Table 1: Number of Products under Development for Tuberculosis 9
Table 2: Number of Products under Development by Companies Tuberculosis 11
Table 3: Number of Products under Development by Universities/Institutes Tuberculosis 14
Table 4: Products under Development by Companies Tuberculosis 16
Table 5: Products under Development by Universities/Institutes Tuberculosis 21
Table 6: Number of Products under Development for Diphtheria 25
Table 7: Number of Products under Development by Companies Diphtheria 27
Table 8: Number of Products under Development by Universities/Institutes Diphtheria 28
Table 9: Products under Development by Companies Diphtheria 29
Table 10: Products under Development by Universities/Institutes Diphtheria 31
Table 11: Number of Products under Development for Pertussis (Whooping Cough) 32
Table 12: Number of Products under Development by Companies Pertussis (Whooping Cough) 34
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1877889
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us ;
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow us on Blogger at : https://marketreportandanalysis.blogspot.com
No comments:
Post a Comment